1-5 of 5
Kudrat M Abdulkadyrov
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Jesús F San Miguel, MD PhD, Rudolf Schlag, MD, Nuriet K Khuageva, MD, Meletios Athanasios Dimopoulos, MD, Ofer Shpilberg, MD, MPH, Martin Kropff, MD, Ivan Spicka, MD, PhD, Maria T Petrucci, Antonio Palumbo, MD, Olga S Samoilova, MD, Anna Dmoszynska, Kudrat M Abdulkadyrov, Prof, Michel Delforge, MD, PhF, Bin Jiang, María-Victoria Mateos, MD, PhD, Kenneth C. Anderson, MD, Dixie-Lee Esseltine, MD, FRCPC, Kevin Liu, PhD, William M Deraedt, PhD, Andrew Z Cakana, MD, FRCPath, Helgi van de Velde, MD, PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 476.
https://doi.org/10.1182/blood.V118.21.476.476
Published: 2011
Journal Articles

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, Nuriet K Khuageva, Meletios A. Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Spicka, Maria Teresa Petrucci, Antonio Palumbo, MD, Olga S Samoilova, Anna Dmoszynska, Kudrat M Abdulkadyrov, Rik Schots, Bin Jiang, Dixie-Lee Esseltine, Kevin Liu, Andrew Z Cakana, Helgi van de Velde, Jesús F. San Miguel
Journal: Blood
Blood (2009) 114 (22): 3859.
https://doi.org/10.1182/blood.V114.22.3859.3859
Published: 2009
Journal Articles

ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis.

Kudrat M. Abdulkadyrov, M.D., Ph.D., Galina N. Salogub, M.D., Ph.D., Nuriet K. Khuazheva, M.D., Ph.D., Rachel Woolf, Eric Haltom, Niels G. Borgstein, MD, Robert Knight, MD, Gary Renshaw, DO, Yijun Yang, Matthew L. Sherman, MD
Journal: Blood
Blood (2009) 114 (22): 749.
https://doi.org/10.1182/blood.V114.22.749.749
Published: 2009
Journal Articles

Characterization of Patients with Multiple Myeloma Achieving Complete Response to Bortezomib: An Interim Report From An International Electronic Observational Study.

Michel Delforge, MD, PhD, Hadewijch De Samblanx, Maria Roussou, Konstantinos Zervas, Eirini Katodritou, Kudrat M Abdulkadyrov, Deniz Sargin, Cyrille Hulin, Lucia Ahlberg, Javier de la Rubia, Rita Ganguly, Joris Diels, Ravinder Dhawan, Meletios A. Dimopoulos
Journal: Blood
Blood (2009) 114 (22): 4938.
https://doi.org/10.1182/blood.V114.22.4938.4938
Published: 2009
Journal Articles

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Jesus F San Miguel, Rudolf Schlag, Nuriet K Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Ivan Spicka, Maria Teresa Petrucci, Antonio Palumbo, Olga S Samoilova, Anna Dmoszynska, Kudrat M Abdulkadyrov, Rik Schots, Bin Jiang, Maria-Victoria Mateos, Kenneth C Anderson, Dixie-Lee Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Paul Richardson
Journal: Blood
Blood (2008) 112 (11): 650.
https://doi.org/10.1182/blood.V112.11.650.650
Published: 2008